Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ: ORMP · IEX Real-Time Price · USD
6.51
+0.03 (0.46%)
Oct 3, 2022 4:00 PM EDT - Market closed
0.46%
Market Cap 252.76M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 38.83M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 149,792
Open 6.53
Previous Close 6.48
Day's Range 6.31 - 6.62
52-Week Range 3.59 - 31.54
Beta 2.31
Analysts Buy
Price Target 32.30 (+396.2%)
Earnings Date Aug 3, 2022

About ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a w... [Read more...]

Industry Pharmaceuticals
Founded 2002
CEO Nadav Kidron
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ORMP
Full Company Profile

Financial Performance

In 2021, ORMP's revenue was $2.70 million, a decrease of -0.26% compared to the previous year's $2.71 million. Losses were -$22.24 million, 93.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ORMP stock is "Buy." The 12-month stock price forecast is 32.3, which is an increase of 396.16% from the latest price.

Price Target
$32.3
(396.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment ...

2 weeks ago - PRNewsWire

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

3 weeks ago - PRNewsWire

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

-  ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol -  ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK , July 26, 2022...

2 months ago - PRNewsWire

Why Oramed Pharmaceuticals Stock Is On Fire Today

The biotech's stock has been ripping higher of late.

2 months ago - The Motley Fool

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

NEW YORK , July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

2 months ago - PRNewsWire

Why Oramed Pharmaceuticals Stock Rocketed Higher Today

A reassuring letter to shareholders has the biotech's stock jumping today.

2 months ago - The Motley Fool

Oramed Letter to Shareholders

$169 Million in Cash and Investments Pivotal Phase 3 Oral Insulin Data Expected January 2023 Phase 2 NASH Data Expected This Quarter Oravax - Oral Vaccine NEW YORK , July 7, 2022 /PRNewswire/ -- Oramed ...

2 months ago - PRNewsWire

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

NEW YORK , June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today...

4 months ago - PRNewsWire

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

NEW YORK , May 24, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

4 months ago - PRNewsWire

Oramed to Present at H.C. Wainwright Global Investment Conference

NEW YORK , May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

4 months ago - PRNewsWire

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected in ...

5 months ago - PRNewsWire

Oramed Appoints Yadin Rozov to its Board of Directors

NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announc...

5 months ago - PRNewsWire

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

6 months ago - PRNewsWire

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

NEW YORK, March 22, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

6 months ago - PRNewsWire

Oramed to Present at Barclays Global Healthcare Conference

NEW YORK, March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery system...

6 months ago - PRNewsWire

Oramed Issues Annual Message to Shareholders

NEW YORK, Jan. 12, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today...

8 months ago - PRNewsWire

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platform...

8 months ago - PRNewsWire

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purch...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its...

Other symbols: MYMD
9 months ago - Business Wire

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million...

9 months ago - Market Watch

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million D...

NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

9 months ago - PRNewsWire

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

9 months ago - PRNewsWire

Oramed Pharmaceuticals Appoints Chief Legal Officer

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

9 months ago - PRNewsWire

Oramed to Join MSCI USA Small Cap Index

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

10 months ago - PRNewsWire

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

10 months ago - PRNewsWire

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commerci...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its...

Other symbols: MYMD
10 months ago - Business Wire